Core Viewpoint - Zhonghui Biotech-B (02627) experienced a significant stock price increase, soaring nearly 158% on its debut and continuing to rise over 20% the following morning, with a current price of 39.72 HKD and a market capitalization exceeding 15 billion HKD [1] Company Overview - Zhonghui Biotech focuses on the research, manufacturing, and commercialization of vaccines [1] - The company has two core products: a quadrivalent influenza virus subunit vaccine (approved by the National Medical Products Administration for individuals aged three and above in May 2023, branded as Huiru Kangkang) and an in-development lyophilized human rabies vaccine, which is developed using human diploid cells and demonstrates good safety [1] - Additionally, Zhonghui Biotech is working on 11 other vaccine candidates [1] IPO Performance - The IPO public offering of Zhonghui Biotech was oversubscribed by over 4,000 times, with a total subscription amount exceeding 200 billion HKD, making it the "super subscription king" in the Hong Kong stock market's 18A biotech sector this year [1]
中慧生物-B上市次日再涨超20% 昨日飙升近158% 总市值突破150亿港元